# Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)

> **NCT00344825** · — · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 300 (actual)

## Conditions studied

- Leukemia, B-Cell, Chronic

## Interventions

- **DRUG:** Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864)

## Key facts

- **NCT ID:** NCT00344825
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00344825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00344825, "Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00344825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*